Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects

Endocrinol Diabetes Nutr (Engl Ed). 2024 Jan;71(1):4-11. doi: 10.1016/j.endien.2024.02.001.

Abstract

Introduction: Patients with incomplete response to initial therapy of thyroid cancer can be managed with ongoing observation or potentially additional therapies. Our aim was to assess the effect of a second radioactive iodine treatment (RAIT) and its relationship with causes and clinical variables.

Material and methods: Patients undergoing a second RAIT for biochemical or structural incomplete response to initial therapy of DTC were retrospectively included (n=120). They were categorised based on the American Thyroid Association (ATA) classification of response to initial therapy. Patients were reclassified in the following 6-18 months after second RAIT based on imaging findings and measurements of thyroglobulin and antithyroglobulin antibody levels. The associations of a downgrading of response category and progression-free survival (PFS), and the related variables, were evaluated.

Results: Sixty-six patients (55%) had a downgrading on ATA response category after second RAIT. A significant interdependence of causes for second RAIT and outcomes was found (χ2=29.400, p=0.001), with patients with neck reoperation showing a higher rate of indeterminate or excellent responses. A significant association between ATA response to second RAIT and absence of structural progression was found (χ2=44.914, p<0.001), with less structural progression in patients with downgrading on ATA response (χ2=30.914, p<0.001). There was also significant interdependence to some clinical variables, such as AJCC stage (χ2=8.460, p=0.015), ATA risk classification (χ2=10.694, p=0.005) and initial N stage (χ2=8.485, p=0.004).

Conclusions: In selected cases, a second RAIT could lead to more robust responses with a potential improvement in prognosis in patients with incomplete response to initial DTC treatment.

Keywords: Biochemical incomplete response; Cáncer diferenciado de tiroides; Differentiated thyroid cancer; Radioiodine; Radioyodo; Respuesta bioquímica incompleta; Respuesta estructural incompleta; Second radioactive iodine treatment; Segundo tratamiento de radioyodo; Structural incomplete response.

MeSH terms

  • Adenocarcinoma*
  • Humans
  • Iodine Radioisotopes / therapeutic use
  • Retrospective Studies
  • Thyroid Neoplasms* / surgery
  • Thyroidectomy
  • United States

Substances

  • Iodine Radioisotopes